Cargando…

Levodopa Carbidopa Intestinal Gel in Advanced Parkinson’s Disease: DUOGLOBE Final 3-Year Results

BACKGROUND: Levodopa-carbidopa intestinal gel (LCIG) improves motor and non-motor symptoms in patients with advanced Parkinson’s disease (aPD). OBJECTIVE: To present the final 36-month efficacy and safety results from DUOGLOBE (DUOdopa/Duopa in Patients with Advanced Parkinson’s Disease – a GLobal O...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chaudhuri, K. Ray, Kovács, Norbert, Pontieri, Francesco E., Aldred, Jason, Bourgeois, Paul, Davis, Thomas L., Cubo, Esther, Anca-Herschkovitsch, Marieta, Iansek, Robert, Siddiqui, Mustafa S., Simu, Mihaela, Bergmann, Lars, Ballina, Mayra, Kukreja, Pavnit, Ladhani, Omar, Jia, Jia, Standaert, David G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2023
Materias:	Research Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10473130/ https://www.ncbi.nlm.nih.gov/pubmed/37302039 http://dx.doi.org/10.3233/JPD-225105

Ejemplares similares

DUOGLOBE: One‐Year Outcomes in a Real‐World Study of Levodopa Carbidopa Intestinal Gel for Parkinson's Disease
por: Standaert, David G., et al.
Publicado: (2021)

Outcomes Impacting Quality of Life in Advanced Parkinson’s Disease Patients Treated with Levodopa-Carbidopa Intestinal Gel
por: Kovács, Norbert, et al.
Publicado: (2022)

Levodopa-Carbidopa Intestinal Gel Monotherapy: GLORIA Registry Demographics, Efficacy, and Safety
por: Poewe, Werner, et al.
Publicado: (2019)

The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on ‘Off’-time in Patients with Advanced Parkinson’s Disease: A Systematic Review
por: Antonini, Angelo, et al.
Publicado: (2021)

Patterns of Daily Motor-Symptom Control with Carbidopa/Levodopa Enteral Suspension Versus Oral Carbidopa/Levodopa Therapy in Advanced Parkinson’s Disease: Clinical Trial Post Hoc Analyses
por: Pahwa, Rajesh, et al.
Publicado: (2022)

Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Patients with Advanced Parkinson's Disease Receiving ≥2000 mg Daily Dose of Levodopa
por: Zadikoff, Cindy, et al.
Publicado: (2020)

Implementing Levodopa‐Carbidopa Intestinal Gel for Parkinson Disease: Insights from US Practitioners
por: Burack, Michelle, et al.
Publicado: (2018)

Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson’s Disease in the United States
por: Amjad, Fahd, et al.
Publicado: (2019)

Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa
por: Othman, Ahmed A., et al.
Publicado: (2017)

Comparison of the pharmacokinetics of an oral extended‐release capsule formulation of carbidopa‐levodopa (IPX066) with immediate‐release carbidopa‐levodopa (Sinemet(®)), sustained‐release carbidopa‐levodopa (Sinemet(®) CR), and carbidopa‐levodopa‐entacapone (Stalevo(®))
por: Hsu, Ann, et al.
Publicado: (2015)

Levodopa–carbidopa intestinal gel in advanced Parkinson’s disease: long-term results from COSMOS
por: Fasano, Alfonso, et al.
Publicado: (2023)

Systematic evaluation of levodopa-carbidopa intestinal gel patient-responder characteristics
por: Standaert, David G., et al.
Publicado: (2018)

Levodopa–carbidopa intestinal gel in a subgroup of patients with dyskinesia at baseline from the GLORIA Registry
por: Poewe, Werner, et al.
Publicado: (2019)

Effects of levodopa/carbidopa intestinal gel versus oral levodopa/carbidopa on B vitamin levels and neuropathy
por: Loens, Sebastian, et al.
Publicado: (2017)

Levodopa/carbidopa: Hallucinations: case report
Publicado: (2022)

Reply to letter: Suicide in Parkinson's disease patients treated with levodopa‐carbidopa Intestinal Gel
por: Fernandez, Hubert H., et al.
Publicado: (2015)

Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson’s Disease Patients
por: Müller, Thomas, et al.
Publicado: (2022)

Patient and caregiver outcomes with levodopa-carbidopa intestinal gel in advanced Parkinson’s disease
por: Valldeoriola, Francesc, et al.
Publicado: (2021)

Xanthonychia Due to Staining From Carbidopa-Levodopa
por: Hwang, Jonathan Kyle, et al.
Publicado: (2023)

Concomitant Medication Usage with Levodopa‐Carbidopa Intestinal Gel: Results from the COSMOS Study
por: Fasano, Alfonso, et al.
Publicado: (2021)

A post hoc comparison of levodopa-carbidopa intestinal gel daytime monotherapy vs polytherapy safety and efficacy in patients with advanced Parkinson's disease: Results from 6 phase 3/3b open-label studies
por: Boyd, James T., et al.
Publicado: (2019)

24-Hour Levodopa-Carbidopa Intestinal Gel: Clinical Experience and Practical Recommendations
por: Thakkar, Sandeep, et al.
Publicado: (2021)

Membranous nephropathy associated with the use of levodopa-carbidopa combination
por: Chaitanya, V., et al.
Publicado: (2015)

Liquid Levodopa/Carbidopa: Old Solution, Forgotten Complication
por: Vijiaratnam, Nirosen, et al.
Publicado: (2017)

Coadministration With Carbidopa Enhances the Antimyopic Effects of Levodopa in Chickens
por: Thomson, Kate, et al.
Publicado: (2021)

Effect of Levodopa‐carbidopa Intestinal Gel on Non‐motor Symptoms in Patients with Advanced Parkinson's Disease
por: Standaert, David G., et al.
Publicado: (2017)

Effects of Levodopa-Carbidopa Intestinal Gel on Dyskinesia and Non-Motor Symptoms Including Sleep: Results from a Meta-Analysis with 24-Month Follow-Up
por: Chaudhuri, K. Ray, et al.
Publicado: (2022)

Comparative Effectiveness of Carbidopa–Levodopa Enteral Suspension and Deep Brain Stimulation on Parkinson’s Disease-Related Pill Burden Reduction in Advanced Parkinson’s Disease: A Retrospective Real-World Cohort Study
por: Soileau, Michael J., et al.
Publicado: (2022)

Population Pharmacodynamics of IPX066: An Oral Extended-Release Capsule Formulation of Carbidopa–Levodopa, and Immediate-Release Carbidopa–Levodopa in Patients With Advanced Parkinson’s Disease
por: Mao, Zhongping, et al.
Publicado: (2013)

Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease: A Systematic Review and Meta-Analysis
por: Wang, Libo, et al.
Publicado: (2018)

Improving levodopa delivery: IPX203, a novel extended-release carbidopa-levodopa formulation
por: LeWitt, Peter, et al.
Publicado: (2023)

Advanced Parkinson’s Disease Treatment Simplification and Long-Term Outcomes with Levodopa Carbidopa Intestinal Gel: COSMOS Romanian Subanalysis
por: Simu, Mihaela Adriana, et al.
Publicado: (2021)

Improvement of Primary Writing Tremor in Parkinson’s Disease with Carbidopa/Levodopa
por: Battista, James P., et al.
Publicado: (2015)

Extended-release oral capsule of carbidopa–levodopa in Parkinson disease
por: Margolesky, Jason, et al.
Publicado: (2017)

Von Economo’s disease and postencephalitic parkinsonism responsive to carbidopa and levodopa
por: Bigman, Daniel Y, et al.
Publicado: (2018)

Pharmacokinetics of Rytary(®), An Extended-Release Capsule Formulation of Carbidopa–Levodopa
por: Mittur, Aravind, et al.
Publicado: (2017)

Burden of non‐motor symptoms in Parkinson's disease patients predicts improvement in quality of life during treatment with levodopa‐carbidopa intestinal gel
por: Ray Chaudhuri, K., et al.
Publicado: (2018)

The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson’s Disease in England
por: Chaudhuri, K. Ray, et al.
Publicado: (2022)

Predictors of Response for “Off” Time Improvement With Levodopa-Carbidopa Intestinal Gel Treatment: An Analysis of the GLORIA Registry
por: Poewe, Werner, et al.
Publicado: (2020)

Jejunal Infusion of Levodopa–Carbidopa Intestinal Gel Versus Oral Administration of Levodopa–Carbidopa Tablets in Japanese Subjects with Advanced Parkinson’s Disease: Pharmacokinetics and Pilot Efficacy and Safety
por: Othman, Ahmed A., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ekut9n3db2dut4c8jladh7ktbj